Engineered Tolerance: Can CAR-Tregs Reset the Immune System in Vasculitis?

Vasculitis, the family of diseases in which the body’s own immune system attacks blood vessels, remains one of the most stubborn challenges in clinical immunology. Current therapies, from high-dose glucocorticoids to cyclophosphamide and rituximab, can suppress the inflammatory storm, but they rarely restore the deeper problem: a broken system of immune tolerance. A new review published in the Journal of Translational Medicine by Zhiyuan Liu, Shuhui Wang, Haitao Lv and colleagues at Children’s Hospital of Soochow University takes a hard, evidence-based look at whether a next-generation cell therapy, the chimeric antigen receptor-engineered regulatory T cell, or CAR-Treg, could finally close that gap. The authors’ verdict is carefully balanced. Human studies do support the idea that regulatory T cells are quantitatively and functionally abnormal across the major vasculitis subtypes, and early data hint that low-dose interleukin-2 may help expand these cells. Yet no published study has so far demonstrated therapeutic efficacy of CAR-Tregs in any vasculitis model or patient. The therapy, they conclude, is a testable framework rather than an established treatment, and the road to the clinic runs through staged target validation, disease-relevant preclinical models and rigorous safety monitoring.

To understand why the CAR-Treg idea is so compelling, it helps to start with the biology of regulatory T cells themselves. Tregs are a specialized subset of CD4-positive T lymphocytes defined by expression of the transcription factor FOXP3, high levels of the interleukin-2 receptor alpha chain CD25, and low levels of CD127. Their job is to restrain immune responses that would otherwise damage self-tissues. They do this through several complementary mechanisms: secreting anti-inflammatory cytokines such as interleukin-10 and transforming growth factor beta, consuming local interleukin-2 to starve effector T cells, expressing CTLA-4 to strip costimulatory signals from antigen-presenting cells, and releasing granzyme-bearing cytotoxic granules. The integrity of this lineage is tracked molecularly by the Treg-specific demethylated region, or TSDR, a stable epigenetic mark at the FOXP3 locus that distinguishes genuinely stable suppressive cells from unstable, inflammation-induced FOXP3 expressers. When this system fails, either in number or in function, autoimmunity follows, and vasculitis is a prime example of that failure playing out in the vessel wall.

The review systematically assembles the human evidence for Treg dysfunction across the vasculitis spectrum, and the picture that emerges is consistent in direction, if variable in detail. In antineutrophil cytoplasmic antibody-associated vasculitis, or AAV, which includes granulomatosis with polyangiitis and microscopic polyangiitis, patients show reduced circulating Treg frequencies and impaired suppressive capacity, particularly during active disease. The autoantigens in AAV are well defined: myeloperoxidase and proteinase 3, enzymes normally confined to neutrophil granules that become aberrantly displayed on the cell surface and, in genetically susceptible individuals, trigger autoreactive T and B cell responses. In giant cell arteritis and Takayasu arteritis, the large-vessel diseases, Treg abnormalities coexist with a pro-inflammatory Th1 and Th17 milieu that drives granulomatous inflammation of the arterial wall. The authors are careful to grade this evidence, distinguishing direct findings in vasculitis patients from mechanistic work in other autoimmune diseases such as systemic lupus erythematosus and type 1 diabetes, and from untested therapeutic hypotheses. That discipline matters, because the field has repeatedly seen promising immunological correlations fail to translate into clinical benefit.

Against that backdrop, the review evaluates three escalating therapeutic strategies. The first is endogenous Treg expansion, most prominently through low-dose interleukin-2. Because Tregs are exquisitely sensitive to interleukin-2 through their high-affinity CD25-containing receptor, low-dose regimens preferentially activate the STAT5 signaling pathway in Tregs, promoting their survival, proliferation and suppressive function without broadly stimulating conventional T cells. Early human studies in vasculitis provide limited but genuine support for this approach, with signals of biological activity and tolerability. The second strategy is polyclonal Treg transfer, in which Tregs are expanded ex vivo from a patient or donor and reinfused without any antigen specificity. This approach has the advantage of manufacturing simplicity but the disadvantage of diffuse, antigen-agnostic suppression, which may blunt protective immunity and may not concentrate suppressive activity where it is needed: at the inflamed vessel wall.

The third and most technologically ambitious strategy is the antigen-specific engineered Treg, and here the review dives deep into the engineering itself. A CAR-Treg is created by introducing a synthetic receptor into Tregs that combines an extracellular single-chain variable fragment, or scFv, which binds a target antigen directly and HLA-independently, with intracellular signaling domains. First-generation constructs used only CD3-zeta, while second-generation designs add costimulatory modules such as CD28 or 4-1BB, which shape the cells’ metabolic fitness, proliferative capacity and stability. For Tregs specifically, the choice of signaling domain is not trivial: CD28-based signaling can support FOXP3 stability, whereas 4-1BB-based signaling biases cells toward a more oxidative metabolic profile. The goal is a cell that homes to the site of vascular inflammation, recognizes its target with precision, and delivers localized immunosuppression without systemic immune paralysis. Proposed targets in vasculitis include activated endothelium, marked by molecules such as ICAM-1 and VCAM-1, and the autoreactive responses directed against myeloperoxidase and proteinase 3.

Here the review delivers its most important caveat. Those proposed targets, the authors emphasize, remain design hypotheses. No published study has yet validated a CAR-Treg construct against activated endothelium or against MPO- or PR3-specific autoreactivity in a vasculitis-relevant model, let alone in a patient. The distinction between a plausible target and a validated one is where many cell therapy programs have stumbled. Endothelial targets such as ICAM-1 are expressed not only at sites of vasculitic inflammation but also in ordinary physiological immune responses, raising the specter of off-target suppression of useful immunity. Antigen-specific approaches targeting MPO or PR3 face a different problem: the relevant autoantigens are presented by human leukocyte antigen molecules, which means a truly antigen-specific strategy may need to engage the peptide-HLA complex rather than a bare protein, pushing the design toward T cell receptor-engineered Tregs, or TCR-Tregs, rather than scFv-based CARs. TCR-Tregs offer HLA-restricted, peptide-level specificity, but their manufacture is more complex and their activity depends on the patient’s HLA type, complicating product development.

The review does not treat CAR-Tregs in isolation. It systematically compares them with the competing tolerogenic platforms now in development. TCR-engineered Tregs, as noted, offer fine antigen specificity at the cost of HLA dependence. Tolerogenic dendritic cells, which present antigen in a context that induces rather than breaks tolerance, represent a cell-based vaccination strategy. Treg-biased interleukin-2 agents, including engineered IL-2 muteins and antibody-IL-2 fusion complexes, aim to expand the patient’s own regulatory compartment without ex vivo manipulation. Antigen-specific tolerizing platforms, including nanoparticle-based delivery of self-antigens, seek to re-educate the immune system at the level of antigen presentation. Each platform occupies a different point on the trade-off curve between specificity, manufacturing complexity, and breadth of effect. CAR-Tregs sit at the high-specificity, high-complexity end, which is precisely why the authors insist that translation must be staged rather than rushed.

Manufacturing and safety form another major pillar of the analysis. CAR-Treg production must satisfy good manufacturing practice standards, and the field lacks standardized product-release criteria: what combination of FOXP3 expression, TSDR demethylation, suppressive potency and phenotype purity defines a releasable lot remains unsettled. Safety concerns differ from those of conventional CAR-T cells. Because Tregs are inherently suppressive rather than cytotoxic, the dramatic toxicities seen with CAR-T cancer therapy, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, are expected to be less frequent. But CAR-Tregs carry their own risks: off-target or on-target suppression of protective immunity, infection susceptibility, the possibility that engineered cells lose FOXP3 expression and acquire inflammatory functions under inflammatory conditions, and the long-term uncertainty of any living drug. The review also highlights trajectory control technologies, such as synthetic Notch receptors and logic-gated constructs, that could restrict Treg activation to precise antigen combinations, as well as homing engineering through chemokine receptors like CCR4, CCR9, CXCR3 and CXCR5, and the gut-homing integrin alpha-4-beta-7, to steer cells to inflamed vascular beds.

The regulatory and implementation landscape receives equally sober treatment. Early-phase trials will need carefully selected cohorts, probably patients with active disease and measurable biomarkers such as the Birmingham Vasculitis Activity Score, with long-term safety follow-up built into the protocol from the start. The authors argue for a staged pathway: first validate targets in human tissue and disease-relevant models, then establish standardized manufacturing and release criteria, then proceed to small, biomarker-rich early-phase studies before any consideration of broader deployment. They also acknowledge, transparently, that the review itself used generative AI tools for literature search and language editing, with the authors verifying all content and taking full responsibility for the conclusions, a detail that reflects the evolving norms of contemporary translational science.

The significance of this review lies less in announcing a breakthrough than in drawing an honest map. The immunological rationale for precision tolerance in vasculitis is real: Treg abnormalities are documented in human disease, and the tools of cellular engineering have matured dramatically since CAR-T cells transformed oncology. But the review’s central message is that CAR-Tregs for vasculitis are a hypothesis with a defined testing program, not a therapy on the shelf. If the proposed targets survive validation, if manufacturing can deliver stable, potent, correctly homing cells, and if early trials are designed with the rigor the authors demand, antigen-specific CAR-Tregs could one day offer vasculitis patients something no current drug provides: durable, antigen-specific restoration of immune tolerance without chronic immunosuppression. Until then, the field’s most valuable asset is exactly the kind of disciplined, evidence-graded analysis this review provides, separating what human data actually show from what the field hopes might one day be possible.

Subject of Research: Regulatory T cell dysfunction in vasculitis and the translational development of antigen-specific CAR-Treg therapy for immune tolerance restoration

Article Title: Precision tolerance in vasculitis: from Treg dysfunction to antigen-specific CAR-Treg therapy

Article References: Liu, Z., Wang, S., Li, X., Zhang, J., Li, J., Liu, Y., Wang, Y., & Lv, H. (2026). Precision tolerance in vasculitis: from Treg dysfunction to antigen-specific CAR-Treg therapy. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08956-8

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08956-8

Keywords: vasculitis, regulatory T cells, CAR-Tregs, immune tolerance, autoimmune disease, precision immunotherapy, interleukin-2, ANCA-associated vasculitis, cell therapy, FOXP3, translational medicine, endothelium